Name | Number of supported studies | Average coverage | |
---|---|---|---|
hematopoietic stem cell | 8 studies | 66% ± 9% | |
hematopoietic precursor cell | 4 studies | 67% ± 12% | |
group 3 innate lymphoid cell | 4 studies | 35% ± 10% | |
innate lymphoid cell | 3 studies | 28% ± 9% |
Insufficient scRNA-seq data for expression of SPINK2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 71% | 18.57 | 462 / 653 | 95% | 8.84 | 577 / 605 |
ureter | 0% | 0 | 0 / 0 | 100% | 11.12 | 1 / 1 |
spleen | 95% | 48.76 | 228 / 241 | 0% | 0 | 0 / 0 |
prostate | 69% | 84.38 | 168 / 245 | 25% | 1.37 | 125 / 502 |
lung | 31% | 4.96 | 179 / 578 | 55% | 3.73 | 640 / 1155 |
lymph node | 0% | 0 | 0 / 0 | 83% | 33.31 | 24 / 29 |
breast | 56% | 22.24 | 259 / 459 | 24% | 0.67 | 266 / 1118 |
intestine | 57% | 31.32 | 554 / 966 | 23% | 1.14 | 119 / 527 |
uterus | 32% | 8.61 | 55 / 170 | 35% | 1.26 | 160 / 459 |
bladder | 38% | 12.00 | 8 / 21 | 28% | 2.92 | 140 / 504 |
brain | 50% | 9.40 | 1308 / 2642 | 14% | 0.40 | 99 / 705 |
ovary | 24% | 9.62 | 44 / 180 | 39% | 1.10 | 168 / 430 |
stomach | 45% | 12.62 | 161 / 359 | 19% | 0.51 | 53 / 286 |
muscle | 58% | 28.14 | 466 / 803 | 0% | 0 | 0 / 0 |
heart | 53% | 69.10 | 459 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 47% | 1.86 | 21 / 45 |
skin | 32% | 5.73 | 579 / 1809 | 14% | 0.52 | 66 / 472 |
pancreas | 14% | 1.63 | 45 / 328 | 32% | 0.99 | 57 / 178 |
kidney | 26% | 6.83 | 23 / 89 | 17% | 1.26 | 154 / 901 |
esophagus | 16% | 3.81 | 229 / 1445 | 27% | 1.10 | 49 / 183 |
peripheral blood | 43% | 10.64 | 395 / 929 | 0% | 0 | 0 / 0 |
adipose | 39% | 13.23 | 471 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 25% | 17.53 | 332 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 10% | 1.83 | 27 / 258 | 10% | 0.42 | 22 / 230 |
liver | 5% | 1.75 | 11 / 226 | 1% | 0.07 | 6 / 406 |
eye | 0% | 0 | 0 / 0 | 3% | 0.06 | 2 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1900004 | Biological process | negative regulation of serine-type endopeptidase activity |
GO_0001675 | Biological process | acrosome assembly |
GO_0007286 | Biological process | spermatid development |
GO_0001669 | Cellular component | acrosomal vesicle |
GO_0005576 | Cellular component | extracellular region |
GO_0004866 | Molecular function | endopeptidase inhibitor activity |
GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SPINK2 |
Protein name | Serine protease inhibitor Kazal-type 2 (Acrosin-trypsin inhibitor) (Epididymis tissue protein Li 172) (HUSI-II) Serine peptidase inhibitor Kazal type 2 |
Synonyms | |
Description | FUNCTION: As a strong inhibitor of acrosin, it is required for normal spermiogenesis. It probably hinders premature activation of proacrosin and other proteases, thus preventing the cascade of events leading to spermiogenesis defects . May be involved in the regulation of serine protease-dependent germ cell apoptosis (By similarity). It also inhibits trypsin. . |
Accessions | D6RC51 A0A087WTA9 A0AA34QVT9 ENST00000506738.6 ENST00000618802.3 ENST00000707144.1 D6RI10 ENST00000248701.8 P20155 ENST00000504762.1 |